To cite this paper use one of the standards below:
SARS-CoV-2 infection has a vast spectrum of clinical signs, from asymptomatic to lethal. COVID-19 outcome depends on the control of viral load (resistance) and on the capacity to limit tissue damage (disease tolerance). Severe COVID-19 patients show exacerbated inflammation and tissue dysfunction, being the paradigm of low disease tolerance, whereas patients with low resistance may stay oligosymptomatic despite persistent infection, being unrecognized transmitters. The underlying mechanisms remain unclear. Therefore, here we seek to elucidate immune dynamics involved in this phenomenon.
To that aim, we analyzed PBMCs and plasma from COVID-19 patients with distinct resistance and disease tolerance soon after disease onset (<10 DSSO) (CAAE: 30161620.0.1001.5257; parecer 4.245.490). At the time of sample collection, no patient was hospitalized and all had mild symptoms. Patients with long-term infection (positive DSSO>21, n=28) had fewer circulating NK cells than patients with regular COVID-19 (n=30) or patients progressing to severe disease (oxygen support, n=21). This was in line with lower plasma IFNγ and IL-12. IFNα was not increased in the plasma of these patients, as in the other groups, and PBMCs showed lower induction of interferon-stimulated genes (ISGs), pointing to an impaired antiviral response. On the other hand, patients with worse progression displayed elevated concentrations of IL-9, IL-13 and Eotaxin, indicative of type 2 inflammation. Lower levels of tissue-repair associated growth factors, like FGF and VEGF were also found in the plasma of these patients. Interestingly, their PBMCs showed an induction of the stress response, characterized by increased NRF-2, HMOX-1 and AREG transcripts, probably related to later recovery.
Overall, our study reveals alternative immune strategies to deal with SARS-CoV-2 infection, propose early markers of COVID-19 progression and sheds light on differences in disease tolerance with potential therapeutic value.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper